• Reuters

    U.S. presses TikTok, Meta and X to crack down on antisemitic posts, Bloomberg News reports

    Representatives from companies including Alphabet, Meta, Microsoft, TikTok and X met on Thursday with U.S. special envoy Deborah Lipstadt to monitor and combat antisemitism. Lipstadt requested that each company designate a policy team member to address the issue and conduct training for key personal to identify antisemitism and publicly report trends in anti-Jewish content. "We welcomed this convening and were pleased to come together to share facts about the ongoing steps TikTok takes on this important issue and to continue to learn from experts in the room," a TikTok spokesperson said.

  • Sky News

    Labour pledges to clear backlog of patients waiting over 18 weeks within five years

    Labour will pledge to clear the backlog of patients waiting more than 18 weeks for NHS treatment within five years of government if the party gets into power. Making the announcement in the West Midlands on Wednesday, Sir Keir Starmer will promise to "take the best of the NHS to the rest of the NHS so patients in every part of the country can be treated on time". Measures will include doubling the number of scanners to diagnose patients sooner, using spare capacity in the private sector without charging patients, and delivering what Labour claims will be "the biggest expansion of NHS staff in history".

  • Yahoo Finance Video

    Tapping into the GLP-1 hype? Consider these pharma stocks.

    Enthusiasm for GLP-1 drugs on Wall Street persists, with Eli Lilly (LLY) committing more than $5.3 billion to expand a plant involved in the production of tirzepatide weight-loss and diabetes injections. Jefferies Biotechnology Managing Director Michael Yee joins Market Domination to explain which biotech companies are hidden gems in the GLP-1 craze on Wall Street. "We have said Amgen (AMGN) is one of the most important large-cap companies that we have been very bullish on. And they, too, will go to phase three with a monthly GLP-1. And we think the data is going to be great the end of the year. There's also smaller companies, like Scholar Rock, SRRK, or Corbis that also have new modalities that are interesting," Yee tells Yahoo Finance. For more on the biotech sector and the upcoming annual conference for The American Society of Clinical Oncology, watch the full interview with Michael Yee here: https://finance.yahoo.com/video/biotech-sector-cancer-vaccines-pd-204711308.html  For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino